HPA COMPETITIVE SEAL BID (IFB)

State of Hawaii

Department of Corrections and Rehabilitation
Rehabilitation Services,

Hawaii Paroling Authority

Competitive Seal Bid
IFB No. 26002727

FENTANYL DETECTION, EARLY INTERVENTION – 12 PANEL DRUG TEST KITS, ESTABLISH PRICE LIST CONTRACT FY 2027 (July 1, 2026 – June 30, 2027)

May 11, 2026

Note:

HPA COMPETITIVE SEAL BID (IFB)

Title: Fentanyl Detection, Early Intervention – 12-Panel Drug Testing Kits, Establish Price List Contract FY 2027 (July 1, 2026 – June 30, 2027)

Contract Term: July 1, 2026 – June 30, 2027

1. GENERAL INFORMATION
Issuing Agency: Hawaii Paroling Authority (HPA)
IFB Number: #26002727
Issue Date: May 11, 2026
Proposal Due Date and Time: June 3, 2026, at 4:30 PM HST

Points of Contact
Ms. Chantal James
Staff Services Supervisor
chantal.t.james@hawaii.gov
(808) 587-1291

Ms. Marilou Guieb
Account Clerk IV
marilou.e.guieb@hawaii.gov
(808) 587-5606

Mr. Earl Everett
Acting Program Specialist
earl.l.everett@hawaii.gov
(808) 587-1302

2. PURPOSE
The Hawaii Paroling Authority (HPA) is soliciting competitive sealed bids from qualified vendors to establish a price list contract for the purchase and delivery of urine-based 12-panel drug testing kits.

The testing kits will support HPA's clinical monitoring, compliance supervision, early intervention, and relapse detection efforts for supervised individuals Statewide. The State seeks high-sensitivity testing products capable of identifying low concentrations of controlled substances, including fentanyl, to support treatment compliance and public safety objectives.

All products proposed under this IFB shall meet the minimum specifications and requirements outlined herein.

3. CONTRACT TERM
The contract shall begin on July 1, 2026, or upon full execution of the contract, whichever occurs later, and shall remain in effect through June 30, 2027.

The State reserves the right to extend the contract for up to three (3) additional twelve (12)-month periods, subject to satisfactory contractor performance, continued programmatic need, and availability of funds.

4. SCOPE OF WORK

The Contractor shall furnish integrated urine-based 12-panel drug testing kits capable of detecting the following substances:

- THC
- Buprenorphine (BUP)
- Benzodiazepines (BZO)
- Methadone (MTD)
- Amphetamines (AMP)
- Oxycodone (OXY)
- Opiates (OPI)
- MDMA/Ecstasy
- Cocaine (COC)
- Methamphetamine (mAMP)
- Alcohol (EtG)
- Fentanyl (FEN)

Vendors shall clearly identify the testing methodology and panel configuration proposed.

5. TECHNICAL SPECIFICATIONS

5.1 Regulatory and Compliance Requirements

Proposed products shall:

- Meet Clinical Laboratory Improvement Amendments (CLIA) standards; moderate- or high-complexity tests are acceptable
- Be FDA 510(k)-cleared, where applicable
- Comply with all applicable Federal, State, and Local Laws, Regulations, and Industry Standards

5.2 Clinical Monitoring and Cutoff Requirements

The State requires testing kits designed for clinical monitoring and rehabilitation purposes, emphasizing abstinence verification, treatment compliance, early intervention, and relapse detection rather than impairment testing.

Products shall demonstrate high analytical sensitivity capable of detecting low concentrations of target substances.

Vendors shall provide documented cutoff levels (ng/mL) for each analyte included in the proposed product.

Target Clinical Cutoff Guidance

Substance	Target Cutoff Range
THC	~20 ng/mL
Buprenorphine (BUP)	~5–10 ng/mL
Benzodiazepines (BZO)	~200–300 ng/mL
Methadone (MTD)	~300 ng/mL
Amphetamines (AMP)	~300–500 ng/mL
Oxycodone (OXY)	~100 ng/mL
Opiates (OPI)	~300 ng/mL
MDMA/Ecstasy	~300–500 ng/mL
Cocaine (COC)	~150–300 ng/mL
Methamphetamine (mAMP)	~300–500 ng/mL
Alcohol (EtG)	~100–300 ng/mL
Fentanyl (FEN)	~1 ng/mL

These target ranges reflect HPA's clinical monitoring objectives and preference for highly sensitive testing capable of identifying trace substance use and early relapse indicators.

Any deviation from the target cutoff ranges must be clearly identified and supported with technical documentation and justification.

Preference may be given to products meeting clinical-grade, forensic-use, or equivalent industry standards.

5.3 Shelf-Life Requirements

- Products shall have a minimum shelf life of twelve (12) months upon delivery.
- Vendors shall identify expiration dates for all delivered products.

5.4 Product Requirements

Drug testing kits shall:

- Be an integrated 12-panel configuration
- Include fentanyl within the integrated panel configuration
- Not require separate add-on strips or supplemental testing components
- Provide rapid, clear, and easy-to-read results
- Include lot number traceability
- Identify all storage and handling requirements

6. ESTIMATED QUANTITY AND DELIVERY REQUIREMENTS

Estimated Annual Quantity

Approximately 6,000 testing kits annually.

Actual quantities may vary and are not guaranteed.

Ordering and Delivery Requirements

HPA anticipates staggered ordering throughout the contract period.

- Individual orders are expected to range from approximately 100 to 400 kits per shipment
- The HPA Oahu Office shall coordinate and issue purchase orders via email to the awarded vendor identifying the applicable delivery location(s) and shipment quantities for each order, including deliveries to neighbor island offices as needed
- Delivery shall occur within ten (10) calendar days from receipt of order
- Vendors shall utilize expedited shipping methods such as FedEx, USPS Priority Mail, or equivalent services

Delivery Locations

Oahu

- Hawaii Paroling Authority – Oahu Section
  1177 Alakea Street, Ground Level
  Honolulu, HI 96813

Hawai'i Island – Hilo

- Hawaii Paroling Authority – Hilo Section
  1420 Kilauea Avenue, Suite 6
  Hilo, HI 96720

Hawai'i Island – Kona

- Hawaii Paroling Authority – Kona Section
  75-184 Hualalai Road, Suite 103
  Kailua-Kona, HI 96740

Maui

- Hawaii Paroling Authority – Maui Section
  1797-2 Wili Pa Loop
  Wailuku, HI 96793

Kaua'i

- Hawaii Paroling Authority – Kaua'i Section
  2970 Kele Street, Suite 103
  Lihue, HI 96766

Shipping charges, if applicable, shall be separately identified on invoices.

7. PRICING

Vendors shall submit:

- Unit pricing per kit based on estimated order quantities of 100–400 kits
- Total estimated annual cost based on 6,000 kits
- Any applicable volume or bulk purchase discounts
- Any shipping charges, if applicable

All pricing shall remain firm throughout June 30, 2027, including any authorized extension periods.

8. EVALUATION CRITERIA
Awards shall be made to the responsive and responsible bidder whose proposal is determined to be most advantageous to the State.

Evaluation factors may include:
- Compliance with required integrated 12-panel configuration
- Inclusion of fentanyl detection capabilities
- Compliance with technical specifications and cutoff requirements
- Unit and total pricing
- Product shelf life
- Delivery capabilities and lead times
- Product suitability for clinical monitoring and early intervention objectives
- Vendor reliability, responsiveness, and completeness of proposal submission

The State reserves the right to:
- Reject any or all bids
- Conduct discussions with bidders
- Request Best and Final Offers (BAFO)
- Award without further discussions, if deemed in the State's best interest

9. VENDOR QUALIFICATIONS
Vendors shall:
- Be actively registered and compliant within Aloha eBUYS, HIePRO, and Hawaii Compliance Express (HCE)
- Be authorized distributors or manufacturers of the proposed products
- Provide product specifications, certifications, and supporting documentation upon request

10. SUBMISSION INSTRUCTIONS
Proposals shall be submitted electronically through HIePRO no later than:

June 3, 2026, at 4:30 PM HST

Late submissions may not be accepted.

Submission packages shall include:
- Completed pricing proposal
- Product specifications and manufacturer cut sheets
- Cutoff level documentation
- Delivery schedule and lead-time information
- Identification of any exceptions or deviations from IFB requirements

10.1 Product Cut Sheets and Clinical Documentation

Vendors shall provide detailed product cut sheets and specification documentation demonstrating compliance with the clinical monitoring standards identified in this IFB.

Documentation shall include, at a minimum:

- Identification of all analytes included in the 12-panel configuration
- Clearly stated cutoff levels (ng/mL) for each analyte
- Product classification (clinical-grade, forensic-use, or equivalent)
- Testing methodology and sensitivity information
- Applicable certifications, approvals, or regulatory designations

Failure to provide sufficient supporting documentation may result in disqualification of the proposal.

11. TERMS AND CONDITIONS

- The State reserves the right to reject any or all proposals.
- The State may cancel this IFB at any time if determined to be in the best interest of the State.
- Issuance of this IFB does not guarantee contract award.
- Any contract resulting from this solicitation shall be subject to all applicable State procurement laws and administrative rules.

12. QUESTIONS AND COMMUNICATIONS

All questions, requests for clarification, and communications regarding this IFB shall be submitted electronically through HIePRO.

To ensure fairness and transparency, responses to substantive questions may be shared with all prospective offerors through HIePRO.

Contact:

Ms. Chantal James
Staff Services Supervisor
chantal.t.james@hawaii.gov
(808) 587-1291

Ms. Marilou Guieb
Account Clerk IV
marilou.e.guieb@hawaii.gov
(808) 587-5606

Mr. Earl Everett
Acting Program Specialist
earl.l.everett@hawaii.gov
(808) 587-1302